Published in Antimicrob Agents Chemother on May 01, 1996
Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother (2006) 1.14
Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother (1997) 1.07
Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother (2006) 1.04
Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob Agents Chemother (1999) 1.03
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother (1998) 0.97
Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother (2013) 0.87
Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob Agents Chemother (1999) 0.86
The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice. EMBO Mol Med (2012) 0.85
Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine (2006) 0.84
Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother (2004) 0.83
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs (2016) 0.75
Visceral Leishmaniasis as a Possible Reason for Pancytopenia. Front Pediatr (2015) 0.75
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis (1993) 3.30
Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet (1994) 2.70
Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother (1995) 2.11
Prevalence of Leishmania infection among AIDS patients. Lancet (1992) 1.93
Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet (1991) 1.87
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother (1981) 1.82
Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis (1994) 1.79
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet (1992) 1.74
Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg (1995) 1.51
Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect (1990) 1.50
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med (1994) 1.46
Administering amphotericin B--a practical approach. J Antimicrob Chemother (1994) 1.32
Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis (1995) 1.20
Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target (1993) 1.14
Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg (1995) 1.09
AmBisome targeting to fungal infections. Bone Marrow Transplant (1994) 1.07
Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ (1995) 1.06
Visceral leishmaniasis in HIV-infected patients in the south of France. Bull World Health Organ (1995) 1.02
Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother (1984) 1.02
Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother (1992) 1.01
Visceral leishmaniasis as an opportunistic infection in the acquired immunodeficiency syndrome. J Infect (1987) 0.96
Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann Trop Med Parasitol (1992) 0.95
A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses (1993) 0.84
Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS (1993) 0.80
Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Ann Trop Med Parasitol (1994) 0.80
Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J Antimicrob Chemother (1993) 0.80
Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J Clin Microbiol (1997) 3.34
Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother (1995) 2.11
Diagnosis of infections caused by Enterocytozoon bieneusi and Encephalitozoon intestinalis using polymerase chain reaction in stool specimens. AIDS (1997) 2.01
Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis (1996) 1.89
Molecular epidemiology of nosocomial invasive aspergillosis. J Clin Microbiol (1994) 1.87
A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol (2003) 1.73
Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol (2001) 1.58
Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother (1993) 1.51
Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis (1995) 1.50
Comparative performance of impactor air samplers for quantification of fungal contamination. J Hosp Infect (2001) 1.48
Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect (2011) 1.47
Determination of types of Enterocytozoon bieneusi strains isolated from patients with intestinal microsporidiosis. J Clin Microbiol (1998) 1.44
Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis (1992) 1.42
Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet (1996) 1.42
[Cerebral toxoplasmosis concomitant with primary toxoplasma infection in AIDS]. Presse Med (1992) 1.39
High seroprevalence of Encephalitozoon species in immunocompetent subjects. J Infect Dis (1997) 1.38
In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother (1990) 1.38
Detection of microsporidia and identification of Enterocytozoon bieneusi in surface water by filtration followed by specific PCR. J Eukaryot Microbiol (1998) 1.38
Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. J Clin Microbiol (1993) 1.35
Comparative study of tissue culture and mouse inoculation methods for demonstration of Toxoplasma gondii. J Clin Microbiol (1987) 1.34
Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis (1999) 1.33
Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans. Anesth Analg (1986) 1.31
Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis (1999) 1.31
Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features. J Infect Dis (1993) 1.30
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother (1994) 1.24
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother (1993) 1.23
The intestinal elimination of ciprofloxacin in the rat. J Infect Dis (1994) 1.23
[Genotyping of Toxoplasma gondii strains from immunocompromised patients]. Pathol Biol (Paris) (2000) 1.21
Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine. J Antimicrob Chemother (1990) 1.19
In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol (1992) 1.19
[Detection of Toxoplasma gondii by "Polymerase Chain Reaction" (PCR) technique in AIDS infected patients using the repetitive sequence TGR1E]. Pathol Biol (Paris) (1992) 1.18
Detection of microsporidia in surface water: a one-year follow-up study. FEMS Immunol Med Microbiol (2000) 1.17
Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol (1997) 1.17
Toxoplasma gondii: blood and tissue kinetics during acute and chronic infections in mice. Exp Parasitol (1991) 1.16
Early kinetics of Toxoplasma gondii infection in mice infected orally with cysts of an avirulent strain. J Parasitol (1995) 1.16
In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother (1999) 1.12
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother (2000) 1.12
Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther (1999) 1.11
Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology (1988) 1.10
Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis (1998) 1.10
P-glycoprotein expression of the human placenta during pregnancy. Placenta (2005) 1.09
AIDS and strongyloidiasis in Africa. Lancet (1987) 1.09
Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant (1993) 1.08
High-performance liquid chromatographic method for the determination of cefpodoxime levels in plasma and sinus mucosa. J Chromatogr B Biomed Appl (1994) 1.08
Experimental pathogenicity of viscerotropic and dermotropic isolates of Leishmania infantum from immunocompromised and immunocompetent patients in a murine model. FEMS Immunol Med Microbiol (1997) 1.07
Microsporidiosis due to Enterocytozoon bieneusi infection as a possible cause of traveller's diarrhea. Eur J Clin Microbiol Infect Dis (1998) 1.05
Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg (1996) 1.04
Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta (2000) 1.03
Design of a one-tube hemi-nested PCR for detection of Toxoplasma gondii and comparison of three DNA purification methods. J Med Microbiol (1999) 1.03
Evaluation of four commercial rapid immunochromatographic assays for detection of Cryptosporidium antigens in stool samples: a blind multicenter trial. J Clin Microbiol (2011) 1.02
Chronic alcoholism increases the induction dose of propofol in humans. Anesth Analg (1993) 1.02
Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother (1999) 1.02
Evidence of different Enterocytozoon bieneusi genotypes in patients with and without human immunodeficiency virus infection. J Clin Microbiol (2001) 1.01
Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet (1985) 1.01
Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. Anesthesiology (1996) 1.00
Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect (2001) 1.00
Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol (2001) 0.99
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother (1996) 0.99
Multicentric evaluation of a new real-time PCR assay for quantification of Cryptosporidium spp. and identification of Cryptosporidium parvum and Cryptosporidium hominis. J Clin Microbiol (2013) 0.99
Disseminated infection due to Encephalitozoon cuniculi in a patient with AIDS: case report and review. HIV Med (2000) 0.98
Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. Infection (2008) 0.97
Detection of Microsporidia, cryptosporidia and Giardia in swimming pools: a one-year prospective study. FEMS Immunol Med Microbiol (2002) 0.97
Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect Immun (2001) 0.97
Determination of the enantiomers of mefloquine in plasma and whole blood using a coupled achiral-chiral high-performance liquid chromatographic system. J Chromatogr (1990) 0.97
[Value and limitations of toxoplasmosis serology in HIV patients]. Pathol Biol (Paris) (1991) 0.96
Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci (1994) 0.96
Evaluation of a new 5'-nuclease real-time PCR assay targeting the Toxoplasma gondii AF146527 genomic repeat. Clin Microbiol Infect (2009) 0.95
Increasing incidence of Trichophyton tonsurans in Paris, France: a 15-year retrospective study. Br J Dermatol (2012) 0.95
Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth (1990) 0.95
Prevalence of pulmonary toxoplasmosis in HIV-infected patients. AIDS (1990) 0.95
Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol (2001) 0.95
Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology (1993) 0.94
Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am J Med (1990) 0.94
Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother (1994) 0.94
Experimental pathogenicity of a presumed monoxenous trypanosomatid isolated from humans in a murine model. J Eukaryot Microbiol (2002) 0.93
Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta (2005) 0.93
[Multicenter study of toxoplasma serology using various commercial ELISA reagents. Work Group Toxoplasmosis of the National Agency for Quality Control in Parasitology]. Bull World Health Organ (1994) 0.93
Nebulizer performance: AFLM study. Association Française de Lutte contre la Mucoviscidose. Respiration (1995) 0.93
Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1996) 0.92
Detection and species identification of intestinal microsporidia by polymerase chain reaction in duodenal biopsies from human immunodeficiency virus-infected patients. J Infect Dis (1996) 0.92
Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant (2005) 0.92
Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1987) 0.92
Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab Dispos (1999) 0.91
Genetic homology among thirteen Encephalitozoon intestinalis isolates obtained from human immunodeficiency virus-infected patients with intestinal microsporidiosis. J Clin Microbiol (2000) 0.91
Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. J Antimicrob Chemother (1997) 0.91
Genetic diversity among Trichophyton mentagrophytes isolates using random amplified polymorphic DNA method. Br J Dermatol (1999) 0.91